These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 36550903)
1. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials. Guan J; Zhang J; Zhang X; Yuan Z; Cheng J; Chen B Medicine (Baltimore); 2022 Dec; 101(50):e32333. PubMed ID: 36550903 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302 [TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L Front Immunol; 2021; 12():731546. PubMed ID: 34484242 [TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies. Sun C; Chen H; Wang Y; Zheng C Hematology; 2023 Dec; 28(1):2181749. PubMed ID: 36892260 [TBL] [Abstract][Full Text] [Related]
7. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials. Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q Front Immunol; 2023; 14():1218258. PubMed ID: 37614237 [TBL] [Abstract][Full Text] [Related]
8. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830 [TBL] [Abstract][Full Text] [Related]
9. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. Hong X; Zhang Y; Chi Z; Xu Q; Lin W; Huang Y; Lin T; Zhang Y Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e20-e30. PubMed ID: 37993317 [TBL] [Abstract][Full Text] [Related]
11. Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review. Wang YZ; Wang JS; Du J; Tang XL; Xiao JP Front Immunol; 2024; 15():1305810. PubMed ID: 38327524 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178 [TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials. Zhang X; Chen L; Zhao Y; Yin H; Ma H; He M Biomed Res Int; 2019; 2019():9283860. PubMed ID: 31950058 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Liu Y; Pan J; Gao F; Xu W; Li H; Qi X Adv Ther; 2023 Feb; 40(2):521-549. PubMed ID: 36399316 [TBL] [Abstract][Full Text] [Related]
15. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895 [TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis. Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J Front Immunol; 2023; 14():1206689. PubMed ID: 37377959 [TBL] [Abstract][Full Text] [Related]
17. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials. Shi Y; Duan J; Guan Q; Xue P; Zheng Y Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis. Huang Z; Li C; Huang Y; Liang W; Tao H Front Immunol; 2024; 15():1425596. PubMed ID: 39100666 [TBL] [Abstract][Full Text] [Related]
19. Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. Inoue T; Narukawa M Cancer Control; 2022; 29():10732748221140694. PubMed ID: 36748438 [TBL] [Abstract][Full Text] [Related]
20. Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. Man J; Millican J; Mulvey A; Gebski V; Hui R JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34084999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]